Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis

Bioscience Reports

Volumn 36, Issue 4, 2016, Pages

  Robert, Sacha ^a   Gicquel, Thomas ^a   Victoni, Tatiana ^b   Valença, Samuel ^c   Barreto, Emiliano ^d   Bailly Maître, Béatrice ^e   Boichot, Elisabeth ^a   Lagente, Vincent ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^e INSERM   (France)

Author keywords

Fibrosis; Inflammasome; Interleukin 1; Liver; Lung; Matrix metalloproteinase; Purinergic receptors; Tissue inhibitors of metalloproteinase (TIMP) 1

Indexed keywords

CRYOPYRIN; GELATINASE B; INFLAMMASOME; MATRIX METALLOPROTEINASE; PURINERGIC P2X7 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

DISEASE ASSOCIATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; HUMAN; LIVER FIBROSIS; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION; UPREGULATION; ANIMAL; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ANIMALS; FIBROSIS; HUMANS; INFLAMMASOMES; INFLAMMATION; MATRIX METALLOPROTEINASES; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84979582064     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20160107     Document Type: Review

References (81)

1. Selman, M., King, T.E. and Pardo, A. (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Int. Med. 134, 136-151
2. Katzenstein, A.L. and Myers, J.L. (1998) Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157, 1301-1315
3. Ward, P.A. and Hunninghake, G.W. (1998) Lung inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 157, S123-S129
4. Kolb, M., Bonniaud, P., Galt, T., Sime, P.J., Kelly, M.M., Margetts, P.J. and Gauldie, J. (2002) Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am. J. Respir. Cell Mol. Biol. 27, 141-150
5. Gauldie, J., Kolb, M. and Sime, P.J. (2002) A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir. Res. 3, 1
6. Poynard, T., Mathurin, P., Lai, C.L., Guyader, D., Poupon, R., Tainturier, M.H., Myers, R.P., Muntenau, M., Ratziu, V. and Manns, M. (2003) A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 38, 257-265
7. Friedman, S.L. (2003) Liver fibrosis - from bench to bedside. J. Hepatol. 38, 38-53
8. Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D. and Brouwer, J.T. (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112, 463-472
9. Vu, T. and Werb, Z. (1998) Gelatinase B: structure, regulation, and function. In Matrix Metalloproteinases (Parks, W.C. and Mecham, R.P., eds), pp. 115-148, Academic Press, San Diego
10. Hu, J., Van den Steen, P.E., Sang, Q.X.A. and Opdenaker, G. (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498
11. Mott, J.D. and Werb, Z. (2004) Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16, 558-564
12. Giannandrea, M. and Parks, W.C. (2014) Diverse functions of matrix metalloproteinases during fibrosis. Dis. Model Mech. 7, 193-203
13. O'Connor, C., Odlum, C., Van Breda, A., Power, C. and Fitzgerald, M.X. (1998) Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax 43, 393-400
14. Gadeck, J.E., Kelman, J.A., Fells, G., Weinberger, S.E., Horwitz, A.L., Reynolds, H.Y., Fulmer, J.D. and Crystal, R.G. (1979) Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. N. Eng. J. Med. 301, 737-742
15. Fukuda, Y., Ishizaki, M., Kudoh, S., Kitaichi, M. and Yamanaka, N. (1998) Localisation of matrix metalloproteinases-l, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest 78, 687-698
16. Hayashi, T., Stetler-Stevenson, W.G., Fleming, M.Y., Fishback, N., Koss, M.N., Liotta, L.A., Ferrans, V.J. and Travis, W.D. (1996) Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am. J. Pathol. 149, 1241-1256
17. Pardo, A., Selman, M., Ramirez, R., Ramos, C., Montaño, M., Stricklin, G. and Raghu, G. (1992) Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lung. Chest 102, 1085-1089
18. Yaguchi, T., Fukuda, Y., Ishizaki, M. and Yamanaka, N. (1998) Immunohistochemical and gelatin zymography studies for matrix metalloproteinases in bleomycin-induced pulmonary fibrosis. Pathol. Int. 48, 954-963
19. Madtes, D.K., Elston, A.L., Kaback, L.A. and Clark, J.G. (2001) Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 24, 599-607
20. Benyon, R.C. and Arthur, M.J. (2001) Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 21, 373-384
21. Duarte, S., Baber, J., Fujii, T. and Coito, A.J. (2015) Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol. 44-46, 147-56
22. Han, Y.P. (2006) Matrix metalloproteinases, the pros and cons, in liver fibrosis. J. Gastroenterol. Hepatol. 21 (Suppl. 3), S88-S91
23. Harty, M.W., Huddleston, H.M., Papa, E.F., Puthawala, T., Tracy, A.P., Ramm, G.A., Gehring, S., Gregory, S.H. and Tracy, Jr, T.F. (2005) Repair after cholestatic liver injury correlates with neutrophil infiltration and matrix metalloproteinase 8 activity. Surgery 138, 313-320
24. Limuro, Y., Nishio, T., Morimoto, T., Nitta, T., Stefanovic, B., Choi, SK., Brenner, D.A. and Yamaoka, Y. (2003) Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124, 445-458
25. Endo, H., Niioka, M., Sugioka, M., Itoh, J., Kameyama, K., Okazaki, I., Ala-Aho, R., Kähäri, V.M. and Watanabe, T. (2011) Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats. Pathobiology 78, 239-252
26. Calabro, S.R., Maczurek, A.E., Morgan, A.J., Tu, T., Wen, V.W., Yee, C., Mridha, A., Lee, M., d'Avigdor, W., Locarnini, S.A. et al. (2014) Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS One 9, e90571
27. Fallowfield, J.E., Mizuno, M., Kendall, T.J., Constandinou, C.M., Benyon, R.C., Duffield, J.S. and Iredale, J.P. (2007) Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178, 5288-5295
28. Knittel, T., Mehde, M., Grundmann, A., Saile, B., Scharf, J.G. and Ramadori, G. (2000) Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem. Cell Biol. 113, 443-453
29. Ramachandran, P. and Iredale, J.P. (2012) Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM 105, 813-817
30. Yu, Q. and Stamenkovic, I. (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14, 163-176 PubMed
31. Brew, K. (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283
32. Visse, R. and Nagase, H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839
33. Wong, S., Belvisi, M.G. and Birrell, M.A. (2005) Profiling of MMP/TIMP gene expression in human and rodent lung samples, and in models of airway inflammation. Proc. Am. Thorac. Soc. 2, A73
34. Manoury, B., Nenan, S., Guénon, I., Lagente, V. and Boichot, E. (2007) Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. Int. Immunopharmacol. 7, 900-911
35. Corbel, M., Caulet-Maugendre, S., Germain, N., Lagente, V. and Boichot, E. (2001) Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor, batimastat. J. Pathol. 193, 538-545
36. Skiles, J.W., Gonnella, N.C. and Jeng, A.Y. (2001) The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 8, 425-474
37. Skotnicki, J.S., Levin, J.I. and Killar, L.M. (1999) Matrix metalloproteinase inhibitors. In Metalloproteinases as Targets for Anti-inflammatory Drugs. Progress in Inflammation Research (Bottomley, K.M.K., Bradshaw, D. and Nixon, J.S., eds), pp. 17-57. Springer, Basel, AG.
38. Wang, X., Fu, X., Brown, P.D., Crimmin, M.J. and Hoffman, R.M. (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54, 4726-4728
39. Watson, S.A., Morris, T.M., Collins, H.M., Bawden, L.J., Hawkins, K. and Bone, E.A. (1999) Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br. J. Cancer 81, 19-23
40. Iredale, J.P., Thompson, A. and Henderson, N.C. (2013) Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim. Biophys. Acta 1832, 876-883
41. Roeb, E., Purucker, E., Breuer, B., Nguyen, H., Heinrich, P.C., Rose-John, S. and Matern, S. (1997) TIMP expression in toxic and cholestatic liver injury in rat. J. Hepatol. 27, 535-544
42. Hu, Y., Li, D.G. and Lu, H.M. (2007) Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene Med. 9, 217-229
43. Wang, K., Lin, B., Brems, J.J. and Gamelli, R.L. (2013) Hepatic apoptosis can modulate liver fibrosis through TIMP1 pathway. Apoptosis 18, 566-577
44. Elsharkawy, A.M., Oakley, F. and Mann, D.A. (2005) The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10, 927-939
45. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., Yanase, K., Namisaki, T., Imazu, H. and Fukui, H. (2002) Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36, 850-860
46. Iredale, J. (2008) Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol. Res. 58, 129-136
47. Yoshiji, H., Kuriyama, S., Miyamoto, Y., Thorgeirsson, U.P., Gomez, D.E., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Tsujinoue, H. et al. (2000) Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32, 1248-1254
48. 4-treated rats. Int. J. Clin. Exp. Pathol. 8, 8912-8920
49. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. and Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241
50. Villani, A.C., Lemire, M., Fortin, G., Louis, E., Silverberg, M.S., Collette, C., Baba, N., Libioulle, C., Belaiche, J., Bitton, A. et al. (2009) Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 41, 71-76
51. Rosengren, H.M., Hoffman, W., Bugbee, B. and Boyle, D.L. (2005) Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann. Rheum. Dis. 64, 708-714
52. Agostini, L., Martinon, F., Burns, K., McDermott, M.F., Hawkins, P.N. and Tschopp, J. (2004) NALP3 Forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325
53. Martinon, F., Burns, K. and Tschopp, J. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417-426
54. Bauernfeind, F.G., Horvath, G., Stutz, A., Alnemri, E.S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B.G., Fitzgerald, K.A. et al. (2009) Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791
55. Kanneganti, T.D., Lamkanfi, M., Kim, Y.G., Chen, G., Park, J.H., Franchi, L., Vandenabeele, P. and Núñez, G. (2007) Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26, 433-443
56. Gasse, P., Mary, C., Guenon, I., Noulin, N., Charron, S., Schnyder-Candrian, S., Schnyder, B., Akira, S., Quesniaux, V.F., Lagente, V. et al. (2007) IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest. 117, 3786-3799
57. Martinon, F., Mayor, A. and Tschopp, J. (2009) The inflammasomes: guardians of the body. Ann. Rev. Immunol. 27, 229-265
58. Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Pétrilli, V., Tschopp, J., Lagente, V., Quesniaux, V.F., Ryffel, B. and Couillin, I. (2009) Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis, Am. J. Resp. Crit. Care Med. 179, 903-913
59. Riteau, N., Gasse, P., Fauconnier, L., Gombault, A., Couegnat, M., Fick, L., Kanellopoulos, J., Quesniaux, V.F., Marchand-Adam, S., Crestani, B. et al. (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 182, 774-783
60. Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, M.P., Weinrauch, Y., Monack, D.M. and Dixit, V.M. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232
61. Lee, K.Y., Ito, K., Hayashi, R., Jazrawi, E.P., Barnes, P.J. and Adcock, I.M. (2006) NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J. Immunol. 176, 603-615
62. Doz, E., Noulin, N., Boichot, E., Guénon, I., Fick, L., Le Bert, M., Lagente, V., Ryffel, B., Schnyder, B., Quesniaux, V.F. and Couillin, I. (2008) Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J. Immunol. 180, 1169-1178
63. Couillin, I., Vasseur, V., Charron, S., Gasse, P., Tavernier, M., Guillet, J., Lagente, V., Fick, L., Jacobs, M., Coelho, F.R. et al. (2009) IL-1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. J. Immunol. 183, 8195-8202
64. Tian, J., Avalos, A.M., Mao, S.Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C. et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496
65. Cammalleri, L. and Malaguarnera, M. (2007) Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int. J. Med. Sci. 4, 83-93
66. Coddou, C., Yan, Z., Obsil, T., Huidobro-Toro, J.P. and Stojilkovic, S.S. (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol. Rev. 63, 641-683
67. Monção-Ribeiro, L.C., Cagido, V.R., Lima-Murad, G., Santana, P.T., Riva, D.R., Borojevic, R., Zin, W.A., Cavalcante, M.C., Riça, I., Brando-Lima, M. et al. (2011) Lipopolysaccharide-induced lung injury: role of P2X7 receptor. Respir. Physiol. Neurobiol. 179, 314-325
68. Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R.M., Curti, A., Idzko, M., Panther, E. and Di Virgilio, F. (2006) The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176, 3877-3883
69. Gicquel, T., Victoni, T., Fautrel, A., Robert, S., Gleonnec, F., Guezingar, M., Couillin, I., Catros, V., Boichot, E. and Lagente, V. (2014) Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages. Clin. Exp. Pharmacol. Physiol. 41, 279-286
70. Gicquel, T., Robert, S., Loyer, P., Victoni, T., Bodin, A., Ribault, C., Gleonnec, F., Couillin, I., Boichot, E. and Lagente, V. (2015) IL-1β production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages. FASEB J 29, 4162-4173
71. Szabo, G. and Csak, T. (2012) Inflammasomes in liver diseases. J. Hepatol. 57, 642-654
72. Mancini, R., Benedetti, A. and Jezequel, A.M. (1994) An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Arch 424, 25-31
73. Gieling, G., Wallace, K. and Han, Y.P. (2009) Interleukin-1 participates in the progression from liver injury to fibrosis Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1324-G1331
74. Watanabe, A., Sohail, M., Gomes, D.A., Hashmi, A., Nagata, J., Sutterwala, F.H., Mahmood, S., Jhandier, M.N., Shi, Y., Flavell, R.A. and Mehal, W.Z. (2009) Inflammasome-mediated regulation of hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1248-G1257
75. Wree, A., McGeough, M.D., Peña, C.A., Schlattjan, M., Li, H., Inzaugarat, M.E., Messer, K., Canbay, A., Hoffman, H.M. and Feldstein, A.E. (2014) NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. (Berl). 92, 1069-1082
76. 4-induced acute liver injury in mice. World J. Gastroenterol. 16, 2771-2779
77. Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.Y., Kurt-Jones, E.A. and Szabo, G. (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin. Invest. 122, 3476-3489
78. Witek, R.P., Stone, W.C., Karaca, F.G., Syn, W.K., Pereirea, T.A., Agboola, K.M., Omenetti, A., Jung, Y., Teaberry, V., Choi, S.S. et al. (2009) Pan-caspase inhibitor VX-166 reduces firbosis in an animal model of nonalcoholic steatoehaptitis. Hepatology 50, 1421-1430
79. Lu, D. and Insel, P.A. (2014) Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis. Am. J. Physiol. Cell Physiol. 306, C779-C788
80. Huang, C., Yu, W., Cui, H., Wang, Y., Zhang, L., Han, F. and Huang, T. (2014) P2X7 blockade attenuates mouse liver fibrosis. Mol. Med. Rep. 9, 57-62 PubMed
81. Chatterjee, S. and Das, S. (2015) P2X7 Receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis. Oxid. Med. Cell Longev. 2015, 172493